Faeth Therapeutics (FTH) Net Income towards Common Stockholders (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Net Income towards Common Stockholders came in at -$170.2 million in Q1 2026, down 2380.13% YoY from $7.5 million in Q1 2025, and down 3508.99% on a QoQ basis from -$4.7 million in Q4 2025.
Faeth Therapeutics (FTH) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$170.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 2380.13% year-over-year to -$170.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$184.5 million (down 535.43% YoY) and the FY2025 annual result came in at -$21.1 million, up 30.08% from the prior year.
- Net Income towards Common Stockholders retreated to -$170.2 million in Q1 2026, from -$4.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$4.6 million in Q3 2025 to a low of -$170.2 million in Q1 2026.
- A 5-year average of -$17.9 million and a median of -$7.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 46.9% — and 2026, when it sank 2380.13%.
- Tracing FTH's Net Income towards Common Stockholders over 5 years: stood at -$12.2 million in 2022, then jumped by 39.39% to -$7.4 million in 2023, then fell by 4.8% to -$7.8 million in 2024, then jumped by 39.29% to -$4.7 million in 2025, then slumped by 3508.99% to -$170.2 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$170.2 million (Q1 2026), -$4.7 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | -16.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.01 Mn |
| Mar 31, 2026 | -170.24 Mn |
| Dec 31, 2025 | -4.72 Mn |
| Sep 30, 2025 | -4.57 Mn |
| Jun 30, 2025 | -4.94 Mn |
| Mar 31, 2025 | -6.86 Mn |
| Dec 31, 2024 | -7.77 Mn |
| Sep 30, 2024 | -7.25 Mn |
| Jun 30, 2024 | -7.14 Mn |
| Mar 31, 2024 | -7.99 Mn |
| Dec 31, 2023 | -7.41 Mn |
| Sep 30, 2023 | -7.12 Mn |
| Jun 30, 2023 | -9.39 Mn |
| Mar 31, 2023 | -10.18 Mn |
| Dec 31, 2022 | -12.23 Mn |
| Sep 30, 2022 | -13.42 Mn |
| Jun 30, 2022 | -10.54 Mn |
| Mar 31, 2022 | -12.41 Mn |
| Dec 31, 2021 | -9.37 Mn |
| Sep 30, 2021 | -9.69 Mn |